CoChat
Cited by 193

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia

Open access
Tambaro, Francesco Paolo, Singh, Harjeet, Jones, Emily, Rytting, Michael, Mahadeo, Kris M., Thompson, Philip, Daver, Naval, DiNardo, Courtney, Kadia, Tapan, Garcia-Manero, Guillermo, Chan, Tim, Shah, Rutul R., Wierda, William G. · 2021 · Leukemia

Abstract

Acute myelogenous leukemia (AML) is a potentially curable disease; 70% of newly diagnosed patients achieve complete remission with first-line therapy, but prognosis worsens for relapsed disease in both pediatric and adult patients. A recent study examined long-term overall survival (OS) in relapsed patients with AML enrolled to nine successive ECOG-ACRIN trials for newly diagnosed AML between 1984 and 2008. Importantly, a median OS of 6 months from relapse and 10% 5-year OS were reported [ 1 ]. Recently, encouraging results were reported for targeted agents against molecular markers associated to the poor prognosis in relapsed disease given as monotherapy or combined with chemotherapy, including FLT3- [ 2 ], IDH1- [ 3 ] and IDH2-inhibitors [ 4 ]. Remarkable results were achieved with CAR-modified T cells targeting CD19 in relapsed/refractory patients with diffuse large B cell lymphoma (DLBCL) [ 5 ] and pediatric B cell acute lymphoblastic leukemia (ALL) [ 6 ] (50–90% CR), which inspired development of CAR-T cellular therapy for other indications, such as AML. Identifying a myeloid target for CAR-T cellular therapy has proven challenging, since surface antigens are shared by malignant myelogenous cells and normal hematopoietic stem cells, potentially resulting in prolonged myelotoxicity when tested in clinical trials. CD33, a member of the sialic acid-binding Ig-like lectin family, is expressed on subpopulations of leukemia cells, including leukemic stem cells, in almost 90% of AML cases as well as on some normal myeloid precursors [ 7 ]. We initiated a single-center, single-arm, Phase I clinical trial (NCT03126864) to investigate the feasibility and safety of autologous T cells, modified to express a CD33-targeted CAR with 4-1BB and CD3ζ endo-domains and co-expressed with truncated human epidermal growth factor receptor (HER1t) [ 8 ], in patients with relapsed/refractory AML. The goals of this Phase I clinical trial were to assess the feasibility and safety of adoptive transfer of the autologous CD33-CAR-T cells identify the recommended Phase II dose. Details of the clinical trial, including product release criteria (Table S1 ), can be found in the Supplementary Material. Ten adults with relapsed/refractory AML were enrolled; 7 were male; median age was 30 (range 18–73) years (Table 1 ). Patients had received a median of 5 (range 3–8) prior treatment regimens; 3 underwent prior allogeneic stem cell transplant. The median percent bone marrow blasts at screening, WBC, the percent peripheral blood blasts and the lymphocyte count at apheresis were 55% (10–88), 1.6/µl (0.5–7.6), 26% (6–80), and 0.63/µl (0.01–1.5), respectively. Apheresis was collected for 8 patients; 4 had CD33-CAR-T cells produced which met release pre-specified release criteria for infusion; 4 had CD33-CAR-T cell product that failed to meet at least one pre-specified release criteria; and 2 patients had rapidly progressive AML and could not undergo apheresis (Table 2 ). Three patients received CD33-CAR-T cells at the first dose level (0.3 × 10 6 CD33-CAR-T/kg) and 1 patient died before receiving their cells. The time from apheresis to CD33-CAR-T cell infusion is shown (Table 1 ). Table 1 Patient characteristics and treatment. Full size table Table 2 Patient outcomes*. Full size table Table 2 summarizes blood cell and cytokine levels pre- and blood cell and cytokine levels, toxicities and outcomes following infusion of CD33-CAR-T cells for all 3 treated patients. No dose-limiting toxicities (DLTs) were observed (Table 2 ) at dose level 1 during the 28-day DLT assessment period. Two patients experienced cytokine release syndrome (CRS) and 1 patient developed immune effector cell-associated neurotoxicity syndrome (ICANS). Adverse events possibly related to CD33-CAR-T cells included a grade 3 tumor lysis syndrome-acute kidney injury, grade 2 mucositis, grade 1 tachycardia for 1 patient; and a second patient experienced grade 2 intermittent orthostatic hypotension, grade 2 increased bilirubin and grade 3 increased ALT and AST. One patient experienced no toxicity. Adverse Events unrelated to the treatment were grade 3 respiratory distress syndrome in one patient and grade 3 febrile neutropenia and grade 4 sepsis and septic shock in another patient. All three patients who received CD33-CAR-T cells have died, due to disease progression. All 3 patients had leukopenia on the day of CD33-CAR-T cell infusion; 2 had circulating blasts. Two methods were used to detect circulating CAR-T cells: flow cytometry with fluorescently labeled cetuximab and digital droplet polymerase chain reaction (ddPCR) for HER1t. CD33-CAR-T cells were detected by both methods. Patient 03 and 11 had CRS and had associated increase in blood IL-6 level. Despite the activity seen, none of the patients met criteria for response to treatment. There was in vivo evidence of CD33-CAR-T cells at this lowest dose level, which was associated with increase in inflammatory cytokine levels (IL6

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41375-021-01232-2

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

    Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413 · cited 2×

    “Remarkable results were achieved with CAR-modified T cells targeting CD19 in relapsed/refractory patients with diffuse large B cell lymphoma (DLBCL) [5] and pediatric B cell acute lymphoblastic leukemia (ALL) [6] (50–90% CR), which inspired development of CAR-T cellular therapy for other indications, such as AML.”
    Result

Cited by

See all 193

Metadata

Authors
Tambaro, F. P., Singh, H., Jones, E., Rytting, M., Mahadeo, K. M., Thompson, P., Daver, N., DiNardo, C., Kadia, T., Garcia-Manero, G., Chan, T., Shah, R. R., & Wierda, W. G.
Venue
Leukemia
Published
2021-04-08
Volume
35
Issue
11
Pages
3282-3286
ISSN
  • 0887-6924 (ISSN-L)
  • 1476-5551
OpenAlex
W3151599062
Cited by
193
References
1
FWCI
8.89
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.